InterVenn
Combines next generation epiproteomics, instrumentation, and deep learning to augment cancer diagnosis, biomarker, and target discovery.
Employees
Enterprise value
$804m—1.2b
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.